Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBI608 with Pemetrexed and Cisplatin in MPM
NCT02347917Phase 2Completed
- Sponsor
- Sumitomo Pharma
- Start
- Feb 2015
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of napabucasin in malignant pleural mesothelioma (MPM) and non-small cell lung cancer (NSCLC), sponsored by Sumitomo Pharma. Primary endpoints: Number of Participants With Adverse Events, Serious Adverse Events and Adverse Drug Reactions at 17 months, Number of Participants With Dose-limiting Toxicities at 23 days and 4 more. Started Feb 2015; status: completed.
02
Drugs
napabucasin
03
Conditions
malignant pleural mesothelioma (MPM)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02347917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02347917.